ReNeuron's Michael Hunt on 'very significant' exosome therapy data

Published on 19th May 2017

Michael Hunt, CFO for ReNeuron Group Plc (LON:RENE), explains to Proactive their latest research which has been presented at a conference in Canada - highlighting the ability of their exosome therapy candidate to target specific organs of the body.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: